Fundz

Servier acquires Day One Biopharmaceuticals for $2.5B

PRIVATEMar 06, 2026

Acquiring Company

Servier

Acquired Company

Day One Biopharmaceuticals

SuresnesBrisbanePharmaceutical ManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Servier has announced the acquisition of Day One Biopharmaceuticals for $21.50 per share, totaling approximately $2.5 billion. This acquisition is aimed at reinforcing Servier's oncology portfolio and enhancing its capabilities in targeted therapies. The transaction is expected to close in the second quarter of 2026, subject to customary conditions.

Company Information

Company

Servier

Location

Suresnes, Ile De France, France

About

We firmly believe that by working with patients, at all stages of the drug life cycle, they will benefit from the most suitable therapeutic solution and the best possible care pathway. To be committed to therapeutic progress is to be committed to health, to be committed to everyone. We therefore pay particular attention to our teams.

Fundz sees it the moment Servier makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Parul
Senior decision-maker at this company
••••••••@••••••••

See Parul's verified email →

Cynthia
Senior decision-maker at this company
••••••••@••••••••

See Cynthia's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Servier's next move

Learn about Strategic plan

Frequently asked

Who acquired Day One Biopharmaceuticals?

Day One Biopharmaceuticals was acquired by Servier, based in Suresnes. The deal was reported on March 6, 2026. We firmly believe that by working with patients, at all stages of the drug life cycle, they will benefit from the most suitable therapeutic solution and the best possible care pathway. Servier is privately held and operates in Pharmaceutical Manufacturing.

When did Servier acquire Day One Biopharmaceuticals?

Servier's acquisition of Day One Biopharmaceuticals was reported on March 6, 2026. Servier has announced the acquisition of Day One Biopharmaceuticals for $21.50 per share, totaling approximately $2.5 billion. This acquisition is aimed at reinforcing Servier's oncology portfolio and enhancing its capabilities in targeted therapies. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Day One Biopharmaceuticals do?

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases. It is privately held, operating in Biotechnology, and is based in Brisbane.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.